| KCNA7 |
|---|
| Full Name | Potassium Voltage-Gated Channel Subfamily A Member 7 |
| Category | Gene |
| Path | /genes/kcna7 |
| Chromosome | 19q13.3 |
| Protein | Potassium voltage-gated channel subfamily A member 7 |
KCNA7 (Potassium Voltage-Gated Channel Subfamily A Member 7) encodes a voltage-gated potassium (Kv) channel subunit belonging to the Kv1 family. This gene is located on chromosome 19q13.3 and is primarily expressed in neuronal and cardiac tissues. Kv channels are essential for regulating membrane potential and cellular excitability.
KCNA7 forms voltage-gated potassium channels that play critical roles in cellular physiology:
- Neuronal Repolarization: Following action potential depolarization, KCNA7 channels contribute to rapid membrane repolarization, enabling normal neuronal firing patterns
- Calcium Channel Inhibition: Voltage-gated potassium channels regulate calcium influx by controlling the duration of depolarization
- Neurotransmitter Release: By modulating action potential duration, KCNA7 affects calcium entry through voltage-gated calcium channels and subsequent neurotransmitter release
- Muscle Function: In cardiac tissue, KCNA7 contributes to the repolarization phase of the cardiac action potential
KCNA7 mutations and dysregulation have been linked to several conditions:
- Cardiac Arrhythmias: Altered KCNA7 function can contribute to Long QT syndrome and other cardiac rhythm disorders
- Neurological Disorders: Kv channel dysfunction has been implicated in:
- Epilepsy
- Ataxia
- Myasthenia gravis
- Neurodegeneration: Potassium channel alterations are observed in Alzheimer's and Parkinson's disease
KCNA7 shows tissue-specific expression:
- Brain: Highest expression in hippocampus and cerebral cortex
- Heart: Significant expression in cardiac myocytes
- Skeletal muscle: Moderate expression
- Other tissues: Lower expression in kidney, lung, and pancreas
KCNA7 channels exhibit typical Kv1 family characteristics:
- Rapid activation and inactivation kinetics
- Voltage-dependent gating
- Sensitivity to tetraethylammonium (TEA) and other Kv channel blockers
Kv channel modulators are being investigated for treating various conditions:
- Antiarrhythmic drugs: Targeting cardiac Kv channels
- Neuroprotective agents: Modulating neuronal Kv channels in stroke and neurodegeneration
- Antiepileptic drugs: Some AEDs target voltage-gated potassium channels
- KCNA7 characterization and functional analysis (2017)
- Voltage-gated potassium channels in neuronal excitability (2020)
- Potassium channel mutations in cardiac disease (2018)